Home · TRON Translational Oncology Mainz

This website requires Javascript for some parts to function properly. Your experience may vary.

November 10th, 2026

curATalk seminar series

How does the human heart change from birth to adulthood, and what can these changes teach us about cardiac regeneration? On November 17th, we are pleased to welcome Dr. Dr. Christoph Sandmann from Harvard Medical School in Boston as the speaker of our next curATalk about “Cells of the Human Heart from Birth to Adulthood: Implications for Cardiac Regeneration”.

November 5th, 2026

Computational Biology PhD Symposium fosters scientific exchange in Mainz

Scientific discussions, fresh perspectives, and valuable networking opportunities took center stage at this year's Computational Biology PhD Symposium. Researchers and PhD students from TRON and IMB, and the wider Rhine-Main scientific community gathered in Mainz to share their work and strengthen interdisciplinary collaboration in computational biology.

November 2nd, 2026

Seminars in Translational Science

Dr. Afsar Ali Mian from the Aga Khan University, Karachi, Pakistan, will be our guest on November 2nd. His talk, “Druggable Gene Editing Tools for Treating β-Thalassemia and Sickle Cell Disease”, will offer insights into his research on genome editing, regenerative medicine, and innovative therapeutic approaches for hematological and inherited disorders.

October 26th, 2026

We are saddened by the passing of our Supervisory Board member, Univ.-Prof. Dr. Dr. h.c. mult. Ernst Theodor Rietschel

With the passing of Ernst Rietschel, we mourn the loss of an internationally renowned scientist, a wise advisor, and a person who was closely connected to TRON. We are deeply grateful to him for his trusting collaboration and his many years of dedication.

October 20th, 2026

Seminars in Translational Science

Prof. Dr. Dr. Thomas Grünewald from the German Cancer Research Center (DKFZ) and Hopp Children’s Cancer Center (KiTZ) Heidelberg will be our guest at TRON on October 26th. His talk, “Translational genomics and target therapy of pediatric sarcomas”, will offer insights into his research on the molecular mechanisms of cancer and new approaches to diagnosis and treatment.

October 13th, 2026

Seminars in Translational Science

Professor Nikolaus Rajewsky from the Max Delbrück Center - Berlin Institute for Medical Systems Biology (MDC-BIMSB) will join us at TRON on October 19th. His talk, “Molecular Mechanisms from spatial Omics”, will offer insights into his groundbreaking research in systems biology.

We are TRON

TRON is an independent non-profit translational research organization. We pursue new diagnostics and drugs for the treatment of diseases with high medical need. We apply our transdisciplinary competencies in genomics and immunology to develop novel platforms for the identification and validation of ‘omics’-based biomarkers, to modulate immune system components for use in personalized therapies. Collaborating with academia and industry, TRON executes research at the leading edge to support innovative drug design for human health.

Our new research building

Our new research building is currently under construction on the grounds of Mainz University Medical Center according to a concept by Nickl und Partner architects. This envisions a modern, light-flooded building with laboratory and office areas as well as communication zones with up to 10,800 m² of usable space, which will be integrated into the adjacent green areas and the listed Fichte settlement. As a result of intensive coordination with the city of Mainz and all parties involved, construction preparations have been initiated in record time.

Our Research Focus

TRON conducts collaborative research on disease genomics and therapeutic modulation of the immune system. Specializing in cancer immunology and genomics, our research teams develop tailored bioinformatic and novel biostatistical approaches to identify and characterize disease-relevant molecular targets. We design and improve cutting edge technologies for biomarker discovery and biopharmaceutical development, including platforms for immune-based therapies such as RNA vaccines and cellular therapies.